Drug-loaded nanosystem for treating inflammation, preparation method thereof and application thereof

By loading minocycline hydrochloride on ZIF-8, MINO@ZIF-8 is formed, the antioxidant problem in the treatment of periodontitis is solved, and the synergistic effects of antibacterial, antioxidant and anti-inflammatory are achieved, which significantly improves periodontality The therapeutic effect of inflammation.

CN115887690BActive Publication Date: 2024-11-29SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211033199.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-26
Publication Date
2024-11-29
Estimated Expiration
2042-08-26

AI Technical Summary

Technical Problem

Existing treatments for periodontitis have failed to effectively solve the antioxidant problems in inflammation, resulting in poor treatment effects and antibiotic treatments have drug resistance and side effects.

Method used

Develop an integrated antibacterial, antioxidant and anti-inflammatory drug-loading nanosystem. By loading minocycline hydrochloride on ZIF-8, MINO@ZIF-8 is formed, and ZIF-8 is used to decompose in the acidic microenvironment. Zn ions exert antioxidant and anti-inflammatory effects, and coordinate the antibacterial and anti-inflammatory effects of minocycline hydrochloride.

Benefits of technology

Effective antioxidant and anti-inflammatory effects in acidic microenvironments such as periodontitis are achieved, and the effect of treating periodontitis is improved, especially in the oxidative stress state and inflammatory response caused by bacterial pathogens is significantly alleviated.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115887690B_ABST
    Figure CN115887690B_ABST
Patent Text Reader

Abstract

The present invention discloses a drug-loaded nanosystem for treating periodontitis, a preparation method thereof and its application. The drug-loaded nanosystem is formed by loading minocycline hydrochloride MINO onto ZIF‑8, and the structural formula is MINO@ZIF‑8, wherein the loading amount of MINO on ZIF‑8 is 1%‑5% by mass percentage, and the particle diameter of MINO@ZIF‑8 is controlled within 100nm. The present invention provides a drug-loaded nanosystem integrating antibacterial, antioxidant and anti-inflammatory, MINO and ZIF‑8 synergistically, for preparing a drug for treating periodontitis, in addition to bacterial infection, the continuous oxidative stress state and inflammatory response caused by bacterial pathogens in the progression of periodontitis also have obvious effects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and in particular to a drug-loaded nanometer system for treating inflammation, a preparation method thereof and an application thereof. Background Art

[0002] Periodontitis is a chronic inflammatory disease caused by dental plaque, characterized by gingival bleeding, periodontal pocket formation, connective tissue destruction and alveolar bone resorption leading to early tooth loss. The overall prevalence of periodontitis is 45-50%, and 11.2% of the world's population is affected by severe periodontitis. Periodontitis has become a risk factor for some systemic diseases, including cardiovascular and cerebrovascular diseases, diabetes, Alzheimer's disease, cardiovascular diseases, premature birth, rheumatoid arthritis, digestive system diseases, etc. Therefore, timely and effective treatment of periodontitis is crucial to oral and systemic health.

[0003] Currently, the main treatment for periodontitis is to remove pathogens through mechanical debridement (periodontal scaling, root planing and ultrasonic cavitation) and use topical antibiotics such as minocycline ointment. Doxycycline gel in situ wait.

[0004] From the perspective of the pathogenesis of periodontitis, local antibiotic treatment is the most direct and effective treatment for the initial formation of dental plaque and the release of toxins. Minocycline hydrochloride (MINO) is a semi-synthetic tetracycline and is also a clinical drug. The main ingredient of periodontitis not only has antibacterial and anti-inflammatory effects, but also can prevent periodontal tissue destruction by inhibiting collagenase. However, low pH can cause severe skin irritation and side effects. At the same time, antibiotic treatment has clinical difficulties such as drug resistance and failure of bacterial biofilm. In addition to bacterial infection, the persistent oxidative stress and inflammatory response caused by bacterial pathogens in the progression of periodontitis cannot be ignored. In other words, the treatment of periodontitis requires not only antibacterial but also antioxidant. A two-pronged approach can alleviate the inflammatory process. Current drugs do not consider the antioxidant issue in the treatment of inflammation. Summary of the invention

[0005] In order to solve the above technical problems, the present invention aims to provide an integrated antibacterial, antioxidant and anti-inflammatory drug-carrying nanosystem, in which minocycline hydrochloride and ZIF-8 act synergistically to slowly release and decompose Zn ions in acidic microenvironments such as inflammation, exert their antioxidant and anti-inflammatory effects, and synergize the antibacterial and anti-inflammatory effects of minocycline hydrochloride to treat periodontitis or other inflammatory diseases.

[0006] In order to achieve the above object, the present invention provides a drug-loaded nanosystem for treating inflammation, wherein the drug-loaded nanosystem is formed by loading minocycline hydrochloride MINO onto ZIF-8, and the structural formula is MINO@ZIF-8, wherein the drug loading amount of MINO on ZIF-8 is 1%-10% (by mass percentage), and the particle diameter of MINO@ZIF-8 is controlled within 100nm. The loading amount of MINO can reach 5%, but with the increase of the drug loading ratio, the diameter of the nanoparticles increases, and it is easy to aggregate and precipitate.

[0007] Optionally, the ZIF-8 is prepared by reacting 2-methylimidazole with Zn(NO 3 ) 2 6H 2 O is used as raw material and is formed by reaction at room temperature.

[0008] Optionally, the average particle diameter of MINO@ZIF-8 is 80-100 nm.

[0009] The present invention also provides a method for preparing the drug-loaded nanosystem for treating inflammation, comprising:

[0010] Step 1, mixing 2-methylimidazole and minocycline hydrochloride, and stirring to a clear mixture;

[0011] Step 2: Zn(NO 3 ) 2 6H 2 O solution is poured into the mixed solution of step 1, reacted at room temperature, and post-treated to obtain MINO@ZIF-8.

[0012] Optionally, in step 1, the mass ratio of 2-methylimidazole to minocycline hydrochloride is 15:1 to 100:1.

[0013] Optionally, in step 2, Zn(NO 3 ) 2 6H 2 The mass ratio of O to 2-methylimidazole is 1:10 to 5:10.

[0014] The present invention also provides a use of the drug-loaded nanosystem for treating inflammation, which is used for preparing drugs for treating inflammatory diseases.

[0015] Optionally, it is used to prepare a medicament for treating periodontitis.

[0016] Optionally, it is used to prepare a medicine for treating any one or any two or more of sepsis, bacteremia, folliculitis, pyoderma, tonsillitis, scapulohumeral periarthritis, dacryocystitis, gingivitis, vulvitis, traumatic infection, postoperative infection, and mastitis.

[0017] Beneficial effects of the present invention:

[0018] MINO was loaded onto ZIF-8 to obtain a drug-loaded nanosystem that combines antibacterial, antioxidant and anti-inflammatory properties. MINO and ZIF-8 acted synergistically, and ZIF-8 was degraded to produce Zn in an acidic microenvironment such as periodontitis. 2+ , exerting its antioxidant and anti-inflammatory effects, synergistic with the antibacterial and anti-inflammatory effects of minocycline hydrochloride, and can be used to prepare drugs for the treatment of inflammatory diseases, especially for the preparation of drugs for the treatment of periodontitis. In addition to bacterial infection, it also has obvious effects on the persistent oxidative stress state and inflammatory response caused by bacterial pathogens in the progression of periodontitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The transmission electron microscope, scanning electron microscope and size distribution diagram of ZIF-8 and MINO@ZIF-8MOFs of the present invention are shown.

[0020] Figure 2 This is the ultraviolet absorption spectrum of MINO@ZIF-8MOFs of the present invention.

[0021] Figure 3 The X-ray diffraction (XRD) patterns of ZIF-8 and MINO@ZIF-8 of the present invention are shown in FIG.

[0022] Figure 4 Schematic diagram of the results of the antioxidant test of MINO@ZIF-8 of the present invention.

[0023] Figure 5 Schematic diagram of the results of the anti-inflammatory test of MINO@ZIF-8 of the present invention.

[0024] Figure 6 TEM images of the nanoparticles obtained in Example 2 (a in the figure) and the comparative example (b in the figure). DETAILED DESCRIPTION

[0025] The "co-crystal" described herein refers to an active pharmaceutical ingredient that is combined with a co-crystal former in a crystal lattice through non-covalent bonds, which is a new solid form of drug.

[0026] The calculation method of "drug loading content" described in this article is: drug loading content efficiency (DLC) = (mass of minocycline hydrochloride loaded into nanoparticles) / (mass of nanoparticles) × 100%.

[0027] In the progression of periodontitis, the persistent oxidative stress and inflammatory response caused by bacterial pathogens cannot be ignored. In the local inflammatory response, immune cells produce excessive reactive oxygen species (ROS). Excessive ROS can interfere with the periodontal-related cell cycle process through cell lipid peroxidation and protein and DNA damage, directly leading to oxidative damage to periodontal tissues. Therefore, ROS scavenging drugs or materials are also effective strategies for the treatment of periodontitis. The treatment of periodontitis requires not only antibacterial but also antioxidant. Only a two-pronged approach can alleviate the inflammatory process.

[0028] Zeolitic imidazolate framework 8 (ZIF-8) is a branch of MOF, composed of zinc ions (Zn 2+ ) and 2-methylimidazole (2-MI) to rapidly self-assemble. ZIF-8 can directly encapsulate various substances (such as proteins, nucleic acids and drugs) on demand under mild conditions. At the same time, the nanoparticles have pH-sensitive properties and can be degraded to produce Zn in the acidic microenvironment of periodontitis. 2+ , exerting its pro-antioxidant and anti-inflammatory effects.

[0029] Minocycline hydrochloride (MINO) is a tetracycline drug suitable for the treatment of Staphylococcus, Streptococcus, Pneumococcus, Neisseria gonorrhoeae, Shigella dysenteriae, Escherichia coli, etc. It can treat the following diseases: 1) sepsis, bacteremia; 2) superficial suppurative infections: folliculitis, pyoderma, tonsillitis, periarthritis of shoulder, dacryocystitis, gingivitis, vulvitis, traumatic infection, postoperative infection, etc.; 3) deep suppurative diseases: mastitis.

[0030] The present invention innovatively loads MINO onto ZIF-8 to obtain a drug-loaded nanosystem MINO@ZIF-8 that integrates antibacterial, antioxidant and anti-inflammatory properties. The drug loading amount of MINO on ZIF-8 is 1%-5% (by mass percentage), and the particle diameter of MINO@ZIF-8 is controlled within 100nm (preferably 80-100nm). The active ingredient Zn ions of the present invention can effectively reduce oxidative stress and prevent the production of inflammatory cytokines; MINO and ZIF-8 work synergistically, and in addition to bacterial infection, they also have significant effects on persistent oxidative stress and inflammatory reactions caused by bacterial pathogens.

[0031] The preparation method of the drug-loaded nanosystem MINO@ZIF-8 of the present invention comprises:

[0032] Step 1, mixing 2-methylimidazole and minocycline hydrochloride, dissolving them in methanol, and stirring until clear; wherein the amount of 2-methylimidazole and minocycline hydrochloride used is 15:1 to 100:1 in terms of mass ratio;

[0033] Step 2: Zn(NO 3 )2 6H 2 O is dissolved in ultrapure water solution, stirred evenly and poured into the mixed solution of step 1, reacted at room temperature for 1 to 5 minutes, and post-treated to obtain MINO@ZIF-8. 3 ) 2 6H 2 The mass ratio of O to 2-methylimidazole is 1:10 to 5:10.

[0034] The technical solution of the present invention will be described clearly and completely below in conjunction with the accompanying drawings and embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] Example 1

[0036] ZIF-8MOFs were synthesized by hydrothermal method: 2-Methylimidazole 2-MI (330 mg, 4 mmol) was dispersed in methanol MeOH (10 mL), Zn(NO 3 ) 2 6H 2 O (150 mg, 0.5 mmol) was dissolved in H 2 O (5 mL). After the two solutions were stirred until clear, Zn(NO 3 ) 2 6H 2 The O solution was poured into the 2-MI solution and allowed to react at room temperature for one minute. After centrifugation (10000 rpm, 5 minutes), the milky white solid was collected, washed several times with MeOH, and vacuum dried at 60 °C overnight to remove any residual solvent to obtain ZIF-8MOFs, whose structural characterization is shown in Figure 1 As shown in the figure, a represents the transmission electron microscope TEM image, b represents the scanning electron microscope SEM image, and c represents the size distribution diagram drawn by imageJ software for the diameter measurement of the nanoparticles in the SEM image. It can be seen that ZIF-8MOFs is a very regular dodecahedral structure with sharp edges. Its particle diameter is mainly distributed in the range of 60-70nm, with an average diameter of 63nm. The UV spectrum is shown in the figure Figure 2 As shown, it has a characteristic peak at 210 nm.

[0037] The synthesis of MINO@ZIF-8MOFs was slightly different from the above: the pure 2-MI solution was replaced by a solution mixture containing 2-MI (330 mg, 4 mmol) and minocycline hydrochloride MINO (5.0 mg, 0.0109 mmol). After magnetic stirring until clear, Zn(NO 3) 2 6H 2 O (150 mg, 0.5 mmol) solution was quickly poured into the mixture. After reacting at room temperature for 5 min, the yellow nanoparticles were centrifuged, washed, collected and dried as described above to obtain about 22.5 mg MINO@ZIF-8MOFs with a loading rate of 7.3%. Its structural characterization is shown in Figure 1 As shown. Among them, a' is a transmission electron microscope TEM image, it can be seen that MINO@ZIF-8MOFs presents a regular rhombic dodecahedron structure like simple ZIF-8MOFs, indicating that the drug is successfully loaded into the interior of ZIF-8MOFs rather than adsorbed on the surface. , b' is a scanning electron microscope SEM image, it can be seen that MINO@ZIF-8MOFs are uniform in size and regular in structure, which more intuitively reflects the size of the nanoparticles. c' is a size distribution diagram drawn by measuring the diameter of the nanoparticles in the SEM image using imageJ software. It can be seen that MINO@ZIF-8MOFs is a very regular dodecahedron structure with sharp edges. Its particle diameter is mainly distributed in the range of 80-100nm, with an average diameter of 89nm. The UV-visible absorption spectrum is shown in Figure 2 As shown in the figure, MINO@ZIF-8 has both the characteristic peak wavelength of ZIF-8 at 210 nm and the characteristic peak wavelengths of MINO at 255 nm and 341 nm, proving that the drug MINO is successfully loaded. Figure 3 As shown, the X-ray diffraction (XRD) patterns of ZIF-8 and MINO@ZIF-8 are shown, where both ZIF-8 and MINO@ZIF-8 samples show characteristic diffraction peaks at 2θ of 12.83°, 18.10°, etc., indicating that MINO@ZIF-8 also has a typical ZIF-8 structure with high crystallinity.

[0038] The MINO@ZIF-8 of the present invention has a regular dodecahedral structure. In addition to utilizing the drug function of minocycline hydrochloride itself, the metal ion Zn is introduced 2+ As a therapeutic application, it promotes antioxidant and anti-inflammatory effects, exerting a synergistic effect. The following is an experimental verification of MINO@ZIF-8 for the treatment of periodontitis.

[0039] Antioxidant Test

[0040] Quantitative test of reactive oxygen species ROS, the test method is:

[0041] Two fluorescent probes, 7-dichlorofluorescein diacetate DCFH-DA (Reactive Oxygen Species Detection Kit, Beyotime Biotech, China, S0033M) and red mitochondrial superoxide fluorescent probe MitoSOX (fluorescent dye for mitochondrial superoxide detection, DOJINDO, Japan, MT14) were used to determine the levels of ROS present in cells and mitochondrial tissues, respectively. In vitro, LPS (20 ng / mL) was added to the culture medium to induce inflammation. Human periodontal ligament cells hPDLCs were seeded in 6-well plates under different experimental conditions, washed three times with PBS, and then incubated with DCFH-DA (10 μM) or MitoSOX (0.1 μM) for 30 min in the dark at 37 °C. After incubation, the cells were washed three times with PBS buffer, stained with Hoechst 33342 (nuclear fluorescent dye, Beyotime Biotech, China, C1011), and examined using a fluorescence microscope. To determine the mitochondrial location when detecting MitoSOX, Mitotracker (mitochondrial long-lasting fluorescent probe, DOJINDO Co., Japan, MT10) was stained together with Hoechst 33, 342. ImageJ software (Bethesda, MD, USA) was used to quantify the fluorescence signal intensity.

[0042] Test results such as Figure 4 As shown, (a) whole cell ROS quantification (b) mitochondrial ROS quantification. Lipopolysaccharides (LPS), a periodontal pathogenic substance, can induce the accumulation of reactive oxygen species in gingival epithelial cells, and the antioxidant capacity of MINO@ZIF-8 is higher than that of simple MINO.

[0043] Anti-inflammatory test

[0044] The test method is:

[0045] hPDLCs were plated in six-well plates at 2.0 × 10 5 Cells were grown at a density of 10 cells / well to reach confluence. After incubation for 24 h under various conditions, total RNA was extracted using TRIzol reagent (Takara, Japan) and reverse transcribed using PrimeScriptTM kit (Takara, Japan) according to the manufacturer's instructions. Each inflammatory primer was designed for real-time PCR, and the results were normalized to the mRNA expression level of β-actin and analyzed using the 2-ΔΔCt method.

[0046] like Figure 5The figure shows the quantitative expression level of inflammation-related factors, (c) tumor necrosis factor-α (TNF-α); (d) interleukin 6 (IL-6). The periodontal pathogenic active substance LPS can induce the increased expression of inflammation-related factor proteins in gingival epithelial cells, while ZIF-8 has an anti-inflammatory effect. The anti-inflammatory ability of MINO@ZIF-8 is higher than that of simple MINO.

[0047] Example 2

[0048] 2-MI (330 mg, 4 mmol) and minocycline hydrochloride MINO (10 mg, 0.022 mmol) were added to 10 ml of methanol solution and mixed, and stirred until the mixture was clear.

[0049] After magnetic stirring until clear, Zn(NO 3 ) 2 6H 2 5 ml of ultrapure aqueous solution of O (200 mg, 0.67 mmol) was quickly poured into the mixture. After reacting at room temperature for 5 min, the yellow nanoparticles were centrifuged, washed, collected and dried to obtain 25 mg of MINO@ZIF-8MOFs, the transmission electron microscopy TEM image of which is shown in Figure 6 As shown in a, the average particle diameter is 94 nm and the loading rate is 8.3%. The same method as in Example 1 was used to test the anti-oxidation and anti-inflammatory properties of the sample, which showed that the anti-oxidation and anti-inflammatory properties of the sample were significantly stronger than those of pure MINO.

[0050] Comparative Example

[0051] 2-MI (330 mg, 4 mmol) and minocycline hydrochloride MINO (15 mg, 0.033 mmol) were added to 10 ml of methanol solution and mixed, and stirred until the mixture was clear.

[0052] After magnetic stirring until clear, Zn(NO 3 ) 2 6H 2 5 ml of ultrapure aqueous solution of MINO (150 mg, 0.5 mmol) was quickly poured into the mixture. After reacting at room temperature for 5 min, the yellow nanoparticles were centrifuged, washed, collected and dried to obtain 45 mg of MINO@ZIF-8MOFs. The loading rate of MINO was about 30%. The transmission electron microscope TEM image is shown in the figure. Figure 6 As shown in b, the average particle diameter is 167nm. Figure 6 As can be seen from a and b, with the increase of drug loading, the diameter of nanoparticles increases, the particle shape becomes irregular, and it is easier to agglomerate.

[0053] Some examples also show that with the same mass of reactants, as the reaction time increases, the number of reaction products MINO@ZIF-8MOFs obtained will also increase, and the particle size will also increase.

[0054] In some embodiments, the MINO@ZIF-8 nanoparticles of the present invention can be atomized and then sprayed onto the inflammation site of the patient. MINO@ZIF-8 can also be dispersed in ultrapure water and sprayed onto the inflammation site of the patient.

[0055] In summary, the present invention provides an integrated antibacterial, antioxidant and anti-inflammatory nanomedicine, which is composed of minocycline hydrochloride and a zinc ion eutectic metal organic framework. The diameter of the nanomedicine is about 80-100nm. On the one hand, it can improve the stability and drug loading efficiency of minocycline hydrochloride, realize the controlled release of the drug, and avoid the frequent and excessive use of antibiotics; on the other hand, in vivo and in vitro studies have proved that the nanomedicine can release Zn slowly in an acidic microenvironment. 2+ It has antioxidant and anti-inflammatory capabilities, and works synergistically with minocycline hydrochloride for antibacterial and anti-inflammatory effects, and can be used for the long-term treatment of periodontitis.

[0056] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A drug-loaded nanosystem for treating periodontitis, characterized in that: The drug-loaded nanosystem is formed by loading minocycline hydrochloride MINO onto ZIF-8, and its structural formula is MINO@ZIF-8, wherein the drug loading amount of MINO in ZIF-8 is 1%-10% by mass, and the particle diameter of MINO@ZIF-8 is controlled within 100nm.

2. The drug-loaded nanosystem for treating periodontitis according to claim 1, characterized in that: The ZIF-8 is formed by reacting 2-methylimidazole and Zn(NO3)2·6H2O as raw materials at room temperature.

3. The drug-loaded nanosystem for treating periodontitis according to claim 1, characterized in that: The average particle diameter of MINO@ZIF-8 is 80-100 nm.

4. A method for preparing a drug-loaded nanosystem for treating periodontitis according to any one of claims 1 to 3, characterized in that: The method includes: Step 1, mixing 2-methylimidazole and minocycline hydrochloride, and stirring to a clear mixture; Step 2, pouring Zn(NO3)2·6H2O solution into the mixed solution of step 1, reacting at room temperature, and post-treating to obtain MINO@ZIF-8.

5. The preparation method according to claim 4, characterized in that: In step 1, the mass ratio of 2-methylimidazole to minocycline hydrochloride is 15:1 to 100:

1.

6. The preparation method according to claim 4, characterized in that: In step 2, the mass ratio of Zn(NO3)2·6H2O to 2-methylimidazole is 1:10 to 5:

10.

7. Use of the drug-loaded nanosystem for treating periodontitis according to any one of claims 1 to 3, characterized in that: The invention is used for preparing medicine for treating periodontitis.

Citation Information

Patent Citations

  • Medicine for treating periodontitis and peri-implantitis and preparation method thereof

    CN114601926A

  • Compositions and methods for controlled delivery and protection of therapeutic agents

    WO2021097194A1